Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. Market Dynamics Analysis and Trends

5.1. Market Dynamics

5.1.1. Market Drivers

5.1.2. Market Restraints

5.1.3. Market Opportunities

5.2. Porter’s Five Forces Analysis

5.2.1. Bargaining power of suppliers

5.2.2. Bargaining power of buyers

5.2.3. Threat of substitute

5.2.4. Threat of new entrants

5.2.5. Degree of competition

Chapter 6. Competitive Landscape

6.1.1. Company Market Share/Positioning Analysis

6.1.2. Key Strategies Adopted by Players

6.1.3. Vendor Landscape

6.1.3.1. List of Suppliers

6.1.3.2. List of Buyers

Chapter 7. Global Antibiotics Market, By Drug Class

7.1. Antibiotics Market, by Drug Class, 2023-2032

7.1.1. Cephalosporin

7.1.1.1. Market Revenue and Forecast (2020-2032)

7.1.2. Penicillin

7.1.2.1. Market Revenue and Forecast (2020-2032)

7.1.3. Fluoroquinolone

7.1.3.1. Market Revenue and Forecast (2020-2032)

7.1.4. Macrolide

7.1.4.1. Market Revenue and Forecast (2020-2032)

7.1.5. Carbapenem

7.1.5.1. Market Revenue and Forecast (2020-2032)

7.1.6. Aminoglycoside

7.1.6.1. Market Revenue and Forecast (2020-2032)

7.1.7. Sulfonamide

7.1.7.1. Market Revenue and Forecast (2020-2032)

7.1.8. 7-ACA

7.1.8.1. Market Revenue and Forecast (2020-2032)

7.1.9. 7-Others

7.1.9.1. Market Revenue and Forecast (2020-2032)

Chapter 8. Global Antibiotics Market, By Application

8.1. Antibiotics Market, by Application, 2023-2032

8.1.1. Skin infections

8.1.1.1. Market Revenue and Forecast (2020-2032)

8.1.2. Urinary tract infection

8.1.2.1. Market Revenue and Forecast (2020-2032)

8.1.3. Ear infection

8.1.3.1. Market Revenue and Forecast (2020-2032)

8.1.4. Septicemia

8.1.4.1. Market Revenue and Forecast (2020-2032)

8.1.5. Respiratory infections

8.1.5.1. Market Revenue and Forecast (2020-2032)

8.1.6. Gastrointestinal infections

8.1.6.1. Market Revenue and Forecast (2020-2032)

Chapter 9. Global Antibiotics Market, By Action Mechanism

9.1. Antibiotics Market, by Action Mechanism, 2023-2032

9.1.1. Cell Wall Synthesis Inhibitors

9.1.1.1. Market Revenue and Forecast (2020-2032)

9.1.2. Protein Synthesis Inhibitors

9.1.2.1. Market Revenue and Forecast (2020-2032)

9.1.3. DNA Synthesis Inhibitors

9.1.3.1. Market Revenue and Forecast (2020-2032)

9.1.4. RNA Synthesis Inhibitors

9.1.4.1. Market Revenue and Forecast (2020-2032)

9.1.5. Others

9.1.5.1. Market Revenue and Forecast (2020-2032)

9.1.6. Others

9.1.6.1. Market Revenue and Forecast (2020-2032)

Chapter 10. Global Antibiotics Market, By Drug Origin

10.1. Antibiotics Market, by Drug Origin, 2023-2032

10.1.1. Natural

10.1.1.1. Market Revenue and Forecast (2020-2032)

10.1.2. Synthetic

10.1.2.1. Market Revenue and Forecast (2020-2032)

Chapter 11. Global Antibiotics Market, By Spectrum Of Activity

11.1. Antibiotics Market, by Spectrum Of Activity, 2023-2032

11.1.1. Broad-spectrum Antibiotic

11.1.1.1. Market Revenue and Forecast (2020-2032)

11.1.2. Narrow-spectrum Antibiotic

11.1.2.1. Market Revenue and Forecast (2020-2032)

Chapter 12. Global Antibiotics Market, By Route of Administration

12.1. Antibiotics Market, by Route of Administration, 2023-2032

12.1.1. Oral

12.1.1.1. Market Revenue and Forecast (2020-2032)

12.1.2. Parenteral

12.1.2.1. Market Revenue and Forecast (2020-2032)

Chapter 13. Global Antibiotics Market, By Distribution Channel

13.1. Antibiotics Market, by Distribution Channel, 2023-2032

13.1.1. Retail pharmacies

13.1.1.1. Market Revenue and Forecast (2020-2032)

13.1.2. Online pharmacies

13.1.2.1. Market Revenue and Forecast (2020-2032)

13.1.3. Hospitals

13.1.3.1. Market Revenue and Forecast (2020-2032)

13.1.4. Clinics

13.1.4.1. Market Revenue and Forecast (2020-2032)

Chapter 14. Global Antibiotics Market, Regional Estimates and Trend Forecast

14.1. North America

14.1.1. Market Revenue and Forecast, by Drug Class (2020-2032)

14.1.2. Market Revenue and Forecast, by Application (2020-2032)

14.1.3. Market Revenue and Forecast, by Action Mechanism (2020-2032)

14.1.4. Market Revenue and Forecast, by Drug Origin (2020-2032)

14.1.5. Market Revenue and Forecast, by Spectrum Of Activity (2020-2032)

14.1.6. Market Revenue and Forecast, by Distribution Channel (2020-2032)

14.1.7. Market Revenue and Forecast, by Route of Administration (2020-2032)

14.1.8. U.S.

14.1.8.1. Market Revenue and Forecast, by Drug Class (2020-2032)

14.1.8.2. Market Revenue and Forecast, by Application (2020-2032)

14.1.8.3. Market Revenue and Forecast, by Action Mechanism (2020-2032)

14.1.8.4. Market Revenue and Forecast, by Drug Origin (2020-2032)

14.1.8.5. Market Revenue and Forecast, by Spectrum Of Activity (2020-2032)

14.1.8.6. Market Revenue and Forecast, by Distribution Channel (2020-2032)

14.1.8.7. Market Revenue and Forecast, by Route of Administration (2020-2032)

14.1.9. Rest of North America

14.1.9.1. Market Revenue and Forecast, by Drug Class (2020-2032)

14.1.9.2. Market Revenue and Forecast, by Application (2020-2032)

14.1.9.3. Market Revenue and Forecast, by Action Mechanism (2020-2032)

14.1.9.4. Market Revenue and Forecast, by Drug Origin (2020-2032)

14.1.9.5. Market Revenue and Forecast, by Spectrum Of Activity (2020-2032)

14.1.9.6. Market Revenue and Forecast, by Distribution Channel (2020-2032)

14.1.9.7. Market Revenue and Forecast, by Route of Administration (2020-2032)

14.2. Europe

14.2.1. Market Revenue and Forecast, by Drug Class (2020-2032)

14.2.2. Market Revenue and Forecast, by Application (2020-2032)

14.2.3. Market Revenue and Forecast, by Action Mechanism (2020-2032)

14.2.4. Market Revenue and Forecast, by Drug Origin (2020-2032)

14.2.5. Market Revenue and Forecast, by Spectrum Of Activity (2020-2032)

14.2.6. Market Revenue and Forecast, by Distribution Channel (2020-2032)

14.2.7. Market Revenue and Forecast, by Route of Administration (2020-2032)

14.2.8. UK

14.2.8.1. Market Revenue and Forecast, by Drug Class (2020-2032)

14.2.8.2. Market Revenue and Forecast, by Application (2020-2032)

14.2.8.3. Market Revenue and Forecast, by Action Mechanism (2020-2032)

14.2.8.4. Market Revenue and Forecast, by Drug Origin (2020-2032)

14.2.8.5. Market Revenue and Forecast, by Spectrum Of Activity (2020-2032)

14.2.8.6. Market Revenue and Forecast, by Distribution Channel (2020-2032)

14.2.8.7. Market Revenue and Forecast, by Route of Administration (2020-2032)

14.2.9. Germany

14.2.9.1. Market Revenue and Forecast, by Drug Class (2020-2032)

14.2.9.2. Market Revenue and Forecast, by Application (2020-2032)

14.2.9.3. Market Revenue and Forecast, by Action Mechanism (2020-2032)

14.2.9.4. Market Revenue and Forecast, by Drug Origin (2020-2032)

14.2.9.5. Market Revenue and Forecast, by Spectrum Of Activity (2020-2032)

14.2.9.6. Market Revenue and Forecast, by Distribution Channel (2020-2032)

14.2.9.7. Market Revenue and Forecast, by Route of Administration (2020-2032)

14.2.10. France

14.2.10.1. Market Revenue and Forecast, by Drug Class (2020-2032)

14.2.10.2. Market Revenue and Forecast, by Application (2020-2032)

14.2.10.3. Market Revenue and Forecast, by Action Mechanism (2020-2032)

14.2.10.4. Market Revenue and Forecast, by Drug Origin (2020-2032)

14.2.10.5. Market Revenue and Forecast, by Spectrum Of Activity (2020-2032)

14.2.10.6. Market Revenue and Forecast, by Distribution Channel (2020-2032)

14.2.10.7. Market Revenue and Forecast, by Route of Administration (2020-2032)

14.2.11. Rest of Europe

14.2.11.1. Market Revenue and Forecast, by Drug Class (2020-2032)

14.2.11.2. Market Revenue and Forecast, by Application (2020-2032)

14.2.11.3. Market Revenue and Forecast, by Action Mechanism (2020-2032)

14.2.11.4. Market Revenue and Forecast, by Drug Origin (2020-2032)

14.2.11.5. Market Revenue and Forecast, by Spectrum Of Activity (2020-2032)

14.2.11.6. Market Revenue and Forecast, by Distribution Channel (2020-2032)

14.2.11.7. Market Revenue and Forecast, by Route of Administration (2020-2032)

14.3. APAC

14.3.1. Market Revenue and Forecast, by Drug Class (2020-2032)

14.3.2. Market Revenue and Forecast, by Application (2020-2032)

14.3.3. Market Revenue and Forecast, by Action Mechanism (2020-2032)

14.3.4. Market Revenue and Forecast, by Drug Origin (2020-2032)

14.3.5. Market Revenue and Forecast, by Spectrum Of Activity (2020-2032)

14.3.6. Market Revenue and Forecast, by Distribution Channel (2020-2032)

14.3.7. Market Revenue and Forecast, by Route of Administration (2020-2032)

14.3.8. India

14.3.8.1. Market Revenue and Forecast, by Drug Class (2020-2032)

14.3.8.2. Market Revenue and Forecast, by Application (2020-2032)

14.3.8.3. Market Revenue and Forecast, by Action Mechanism (2020-2032)

14.3.8.4. Market Revenue and Forecast, by Drug Origin (2020-2032)

14.3.8.5. Market Revenue and Forecast, by Spectrum Of Activity (2020-2032)

14.3.8.6. Market Revenue and Forecast, by Distribution Channel (2020-2032)

14.3.8.7. Market Revenue and Forecast, by Route of Administration (2020-2032)

14.3.9. China

14.3.9.1. Market Revenue and Forecast, by Drug Class (2020-2032)

14.3.9.2. Market Revenue and Forecast, by Application (2020-2032)

14.3.9.3. Market Revenue and Forecast, by Action Mechanism (2020-2032)

14.3.9.4. Market Revenue and Forecast, by Drug Origin (2020-2032)

14.3.9.5. Market Revenue and Forecast, by Spectrum Of Activity (2020-2032)

14.3.9.6. Market Revenue and Forecast, by Distribution Channel (2020-2032)

14.3.9.7. Market Revenue and Forecast, by Route of Administration (2020-2032)

14.3.10. Japan

14.3.10.1. Market Revenue and Forecast, by Drug Class (2020-2032)

14.3.10.2. Market Revenue and Forecast, by Application (2020-2032)

14.3.10.3. Market Revenue and Forecast, by Action Mechanism (2020-2032)

14.3.10.4. Market Revenue and Forecast, by Drug Origin (2020-2032)

14.3.10.5. Market Revenue and Forecast, by Spectrum Of Activity (2020-2032)

14.3.10.6. Market Revenue and Forecast, by Distribution Channel (2020-2032)

14.3.10.7. Market Revenue and Forecast, by Route of Administration (2020-2032)

14.3.11. Rest of APAC

14.3.11.1. Market Revenue and Forecast, by Drug Class (2020-2032)

14.3.11.2. Market Revenue and Forecast, by Application (2020-2032)

14.3.11.3. Market Revenue and Forecast, by Action Mechanism (2020-2032)

14.3.11.4. Market Revenue and Forecast, by Drug Origin (2020-2032)

14.3.11.5. Market Revenue and Forecast, by Spectrum Of Activity (2020-2032)

14.3.11.6. Market Revenue and Forecast, by Distribution Channel (2020-2032)

14.3.11.7. Market Revenue and Forecast, by Route of Administration (2020-2032)

14.4. MEA

14.4.1. Market Revenue and Forecast, by Drug Class (2020-2032)

14.4.2. Market Revenue and Forecast, by Application (2020-2032)

14.4.3. Market Revenue and Forecast, by Action Mechanism (2020-2032)

14.4.4. Market Revenue and Forecast, by Drug Origin (2020-2032)

14.4.5. Market Revenue and Forecast, by Spectrum Of Activity (2020-2032)

14.4.6. Market Revenue and Forecast, by Distribution Channel (2020-2032)

14.4.7. Market Revenue and Forecast, by Route of Administration (2020-2032)

14.4.8. GCC

14.4.8.1. Market Revenue and Forecast, by Drug Class (2020-2032)

14.4.8.2. Market Revenue and Forecast, by Application (2020-2032)

14.4.8.3. Market Revenue and Forecast, by Action Mechanism (2020-2032)

14.4.8.4. Market Revenue and Forecast, by Drug Origin (2020-2032)

14.4.8.5. Market Revenue and Forecast, by Spectrum Of Activity (2020-2032)

14.4.8.6. Market Revenue and Forecast, by Distribution Channel (2020-2032)

14.4.8.7. Market Revenue and Forecast, by Route of Administration (2020-2032)

14.4.9. North Africa

14.4.9.1. Market Revenue and Forecast, by Drug Class (2020-2032)

14.4.9.2. Market Revenue and Forecast, by Application (2020-2032)

14.4.9.3. Market Revenue and Forecast, by Action Mechanism (2020-2032)

14.4.9.4. Market Revenue and Forecast, by Drug Origin (2020-2032)

14.4.9.5. Market Revenue and Forecast, by Spectrum Of Activity (2020-2032)

14.4.9.6. Market Revenue and Forecast, by Distribution Channel (2020-2032)

14.4.9.7. Market Revenue and Forecast, by Route of Administration (2020-2032)

14.4.10. South Africa

14.4.10.1. Market Revenue and Forecast, by Drug Class (2020-2032)

14.4.10.2. Market Revenue and Forecast, by Application (2020-2032)

14.4.10.3. Market Revenue and Forecast, by Action Mechanism (2020-2032)

14.4.10.4. Market Revenue and Forecast, by Drug Origin (2020-2032)

14.4.10.5. Market Revenue and Forecast, by Spectrum Of Activity (2020-2032)

14.4.10.6. Market Revenue and Forecast, by Distribution Channel (2020-2032)

14.4.10.7. Market Revenue and Forecast, by Route of Administration (2020-2032)

14.4.11. Rest of MEA

14.4.11.1. Market Revenue and Forecast, by Drug Class (2020-2032)

14.4.11.2. Market Revenue and Forecast, by Application (2020-2032)

14.4.11.3. Market Revenue and Forecast, by Action Mechanism (2020-2032)

14.4.11.4. Market Revenue and Forecast, by Drug Origin (2020-2032)

14.4.11.5. Market Revenue and Forecast, by Spectrum Of Activity (2020-2032)

14.4.11.6. Market Revenue and Forecast, by Distribution Channel (2020-2032)

14.4.11.7. Market Revenue and Forecast, by Route of Administration (2020-2032)

14.5. Latin America

14.5.1. Market Revenue and Forecast, by Drug Class (2020-2032)

14.5.2. Market Revenue and Forecast, by Application (2020-2032)

14.5.3. Market Revenue and Forecast, by Action Mechanism (2020-2032)

14.5.4. Market Revenue and Forecast, by Drug Origin (2020-2032)

14.5.5. Market Revenue and Forecast, by Spectrum Of Activity (2020-2032)

14.5.6. Market Revenue and Forecast, by Distribution Channel (2020-2032)

14.5.7. Market Revenue and Forecast, by Route of Administration (2020-2032)

14.5.8. Brazil

14.5.8.1. Market Revenue and Forecast, by Drug Class (2020-2032)

14.5.8.2. Market Revenue and Forecast, by Application (2020-2032)

14.5.8.3. Market Revenue and Forecast, by Action Mechanism (2020-2032)

14.5.8.4. Market Revenue and Forecast, by Drug Origin (2020-2032)

14.5.8.5. Market Revenue and Forecast, by Spectrum Of Activity (2020-2032)

14.5.8.6. Market Revenue and Forecast, by Distribution Channel (2020-2032)

14.5.8.7. Market Revenue and Forecast, by Route of Administration (2020-2032)

14.5.9. Rest of LATAM

14.5.9.1. Market Revenue and Forecast, by Drug Class (2020-2032)

14.5.9.2. Market Revenue and Forecast, by Application (2020-2032)

14.5.9.3. Market Revenue and Forecast, by Action Mechanism (2020-2032)

14.5.9.4. Market Revenue and Forecast, by Drug Origin (2020-2032)

14.5.9.5. Market Revenue and Forecast, by Spectrum Of Activity (2020-2032)

14.5.9.6. Market Revenue and Forecast, by Distribution Channel (2020-2032)

14.5.9.7. Market Revenue and Forecast, by Route of Administration (2020-2032)

Chapter 15. Company Profiles

15.1. Abbott Laboratories (US)

15.1.1. Company Overview

15.1.2. Product Offerings

15.1.3. Financial Performance

15.1.4. Recent Initiatives

15.2. Pfizer Inc. (US)

15.2.1. Company Overview

15.2.2. Product Offerings

15.2.3. Financial Performance

15.2.4. Recent Initiatives

15.3. Johnson & Johnson Services

15.3.1. Company Overview

15.3.2. Product Offerings

15.3.3. Financial Performance

15.3.4. Recent Initiatives

15.4. GlaxoSmithKline PLC (UK)

15.4.1. Company Overview

15.4.2. Product Offerings

15.4.3. Financial Performance

15.4.4. Recent Initiatives

15.5. Sanofi (France)

15.5.1. Company Overview

15.5.2. Product Offerings

15.5.3. Financial Performance

15.5.4. Recent Initiatives

15.6. Bristol-Myers Squibb Company (US)

15.6.1. Company Overview

15.6.2. Product Offerings

15.6.3. Financial Performance

15.6.4. Recent Initiatives

15.7. Eli Lilly and Company (US)

15.7.1. Company Overview

15.7.2. Product Offerings

15.7.3. Financial Performance

15.7.4. Recent Initiatives

15.8. Novartis AG (Switzerland)

15.8.1. Company Overview

15.8.2. Product Offerings

15.8.3. Financial Performance

15.8.4. Recent Initiatives

15.9. Bayer AG (Germany)

15.9.1. Company Overview

15.9.2. Product Offerings

15.9.3. Financial Performance

15.9.4. Recent Initiatives

15.10. Astellas Pharma Inc. (Japan)

15.10.1. Company Overview

15.10.2. Product Offerings

15.10.3. Financial Performance

15.10.4. Recent Initiatives

Chapter 16. Research Methodology

16.1. Primary Research

16.2. Secondary Research

16.3. Assumptions

Chapter 17. Appendix

17.1. About Us

17.2. Glossary of Terms